Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00730236 · ClinicalTrials.gov registry record · Phase 3
A Safety and Efficacy Study of AEGR-733 to Treat Homozygous Familial Hypercholesterolemia (FH)
A Phase 3 study, sponsored by Aegerion Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 29
- Enrollment target
NCT00730236 is a Phase 3 study that has completed, run by Aegerion Pharmaceuticals. The registered enrollment target is 29 participants.
The verdict
NCT00730236, a Phase 3 study, has completed, sponsored by Aegerion Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 29 participants
- Enrollment target
Study Summary
The goal of this trial is to study the effects of AEGR-733 on LDL cholesterol, other lipids as well as measures of safety over the long-term.
Interventions
- DRUG AEGR-733
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2007-12 |
| Est. Completion | 2011-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00730236
The ClinicalTrials.gov registry entry for NCT00730236 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Aegerion Pharmaceuticals, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AEGR-733 is the first listed.
NCT00730236 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00730236 about?
NCT00730236 is a clinical study titled "A Safety and Efficacy Study of AEGR-733 to Treat Homozygous Familial Hypercholesterolemia (FH)". The goal of this trial is to study the effects of AEGR-733 on LDL cholesterol, other lipids as well as measures of safety over the long-term.
What is the current status of trial NCT00730236?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 29 participants. The study started on 2007-12. Estimated completion is 2011-10.
What interventions are being tested in trial NCT00730236?
The interventions under investigation include: AEGR-733 (DRUG).
Who is sponsoring clinical trial NCT00730236?
This trial is sponsored by Aegerion Pharmaceuticals, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.